Evidence map›Paper›PMID 31228212›Full record

ArticleBrain pathology (Zurich, Switzerland)2020

Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms.

Nina L Fransen, Jakob B A Crusius, Joost Smolders, Mark R Mizee, Corbert G van Eden, Sabina Luchetti, Ester B M Remmerswaal, Jörg Hamann, Matthew R J Mason, Inge Huitinga

Open access · hybridAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Genes · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. CNS demyelination associated with immune dysregulation and a novelMultiple sclerosis (Houndmills, Basingstoke, England) · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nina L FransenDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.ORCID 0000-0003-0958-7162
Jakob B A CrusiusLaboratory for Immunogenetics, Department of Medical Microbiology and Infection Control, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Joost SmoldersDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.ORCID 0000-0001-9766-8661
Mark R MizeeDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Corbert G van EdenDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Sabina LuchettiDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Ester B M RemmerswaalDepartment of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jörg HamannDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Matthew R J MasonDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Inge HuitingaDepartment of Neuroimmunology, The Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Netherlands Institute for Neuroscience · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLAmsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last few decades, several common single nucleotide polymorphisms (SNPs) have been identified that correlate with clinical outcome in multiple sclerosis (MS), but the pathogenic mechanisms underlying the clinical effects of these SNPs are unknown. This is in part because of the difficulty in the functional translation of genotype into disease-relevant mechanisms. Building on our recent work showing the association of clinical disease course with post-mortem MS lesion characteristics, we hypothesized that SNPs that correlate with clinical disease course would also correlate with specific MS lesion characteristics in autopsy tissue. To test this hypothesis, 179 MS brain donors from the Netherlands Brain Bank MS autopsy cohort were genotyped for 102 SNPs, selected based on their reported associations with clinical outcome or their associations with genes that show differential gene expression in MS lesions. Three SNPs linked to MS clinical severity showed a significant association between the genotype and either the proportion of active lesions (rs2234978/FAS and rs11957313/KCNIP1) or the proportion of mixed active/inactive lesions (rs8056098/CLEC16A). Three SNPs linked to MS pathology-associated genes showed a significant association with either proportion of active lesions (rs3130253/MOG), incidence of cortical gray matter lesions (rs1064395/NCAN) or the proportion of remyelinated lesions (rs5742909/CTLA4). In addition, rs2234978/FAS T-allele carriers showed increased FAS gene expression levels in perivascular T cells and perilesional oligodendrocytes, cell types that have been implicated in MS lesion formation. Thus, by combining pathological characterization of MS brain autopsy tissue with genetics, we now start to translate genotypes linked to clinical outcomes in MS into mechanisms involved in MS lesion pathogenesis.

Indexed as

AdultAgedAutopsyBrainCohort StudiesCTLA-4 AntigenDisease Progressionfas ReceptorFemaleGenetic Predisposition to DiseaseGenotypeGray MatterHumansKv Channel-Interacting ProteinsLectins, C-TypeMaleCLEC16A protein, humanCTLA-4 AntigenCTLA4 protein, humanFAS protein, humanfas ReceptorKCNIP1 protein, humanKv Channel-Interacting ProteinsLectins, C-TypeMonosaccharide Transport ProteinsCLEC16AFASmultiple sclerosisNCANneuropathology

Identifiers

PMID31228212
PMCPMC6916567
OpenAlexW2950848789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.